Rhinitis. Vasomotor and allergic rhinitis and Chronic rhinitis, nasopharyngitis and pharyngitis
Conditions
Interventions
Fexofenadine: One tablet per day
Budesonide: One Puff per day.
Treatment - Drugs
Fexofenadine: One tablet per day
Budesonide: One Puff per day
Sponsors
Vice Chancellor for Research and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: the age of man and women between 18 to 60, Signature the testimonial by the patients before entrance to the study, having rhinitis symptoms which is confirmed by specialist physician, lack of abnormality in nasal anatomy, not being suffered from: asthma, infectious disease, underlying diseases such as diabetes and chronic inflammatory diseases. In addition, pregnant women, people above 65 and those people who suffer from rhinitis because of Senility will not enter the study. Exclusion criteria: People suffering from infectious diseases or common cold and patients taking drugs other than drugs that must consume according to the research plan, during Performance of the project? will be excluded. In addition, patients who have a fungal, viral or bacterial disease during the study and patients who do not follow the recommended instructions will be excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GATA3, FOXP3 and RORgt. Timepoint: Befor treatment and After one month treatment. Method of measurement: Relative expression of GATA3, FOXP3 and RORgt measured by Real-time PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Gorgin Karaji
School of Medicine, Kermanshah University of Medical Sciences
Outcome results
None listed